Source:http://linkedlifedata.com/resource/pubmed/id/20191326
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-3-11
|
| pubmed:abstractText |
Tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 are key cytokines involved in lymphoma development. Their pretreatment plasma levels were reported to influence the clinical course of non-Hodgkin's lymphoma. In this study the impact of combined elevation of TNF-alpha and IL-10 on disease features and outcome of patients with diffuse large B-cell lymphoma (DLBCL) were investigated. Plasma TNF-alpha and IL-10 levels were determined at the time of diagnosis in a group of 106 DLBCL patients uniformly treated with anthracycline-based regimens. Three risk groups depending on the pretreatment levels of the cytokines were identified: low-, intermediate-, and high-risk groups. In univariate analysis, the cytokine intermediate- and high-risk groups were associated with lower probability of achieving a complete remission (odds ratio [OR] = 0.2, 95% confidence interval [CI] 0.06-0.6, p = 0.006 and OR = 0.05, 95% CI 0.01-0.2, p < 0.0001, respectively) and shorter progression-free survival (PFS) (OR = 4.4, 95% CI 1.9-10.2, p < 0.001 and OR = 9.7, 95% CI 4.1-23.0, p < 0.0001, respectively) and overall survival (OS) (OR = 4.2, 95% CI 1.7-10.1, p = 0.002 and OR = 11.2, 95% CI 4.4-28.4, p < 0.0001, respectively) in comparison with the cytokine low-risk group. In multivariate analysis, the cytokine intermediate- and high-risk groups also correlated with shorter PFS (relative risk [RR] = 4.5, 95% CI 1.9-10.9, p = 0.001 and RR = 5.8, 95% CI 2.2-15.3, p < 0.0001, respectively) and OS (RR = 4.6, 95% CI 1.8-12.0, p = 0.001 and RR = 7.5, 95% CI 2.7-20.9, p < 0.0001, respectively) regardless of the International Prognostic Index (IPI) scoring system. The TNF-alpha and IL-10 level-based index may work as an additional model to the IPI for predicting the survival of DLBCL patients. This model may help to identify patients in a given IPI risk group for whom more accurate and risk-adapted treatment could be advised.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/IL10 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1661-4917
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
58
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
131-41
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:20191326-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20191326-Biological Markers,
pubmed-meshheading:20191326-Chi-Square Distribution,
pubmed-meshheading:20191326-Cyclophosphamide,
pubmed-meshheading:20191326-Disease-Free Survival,
pubmed-meshheading:20191326-Doxorubicin,
pubmed-meshheading:20191326-Female,
pubmed-meshheading:20191326-Humans,
pubmed-meshheading:20191326-Interleukin-10,
pubmed-meshheading:20191326-Kaplan-Meier Estimate,
pubmed-meshheading:20191326-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:20191326-Male,
pubmed-meshheading:20191326-Middle Aged,
pubmed-meshheading:20191326-Neoplasm Staging,
pubmed-meshheading:20191326-Odds Ratio,
pubmed-meshheading:20191326-Predictive Value of Tests,
pubmed-meshheading:20191326-Prednisone,
pubmed-meshheading:20191326-Proportional Hazards Models,
pubmed-meshheading:20191326-Prospective Studies,
pubmed-meshheading:20191326-Risk Assessment,
pubmed-meshheading:20191326-Risk Factors,
pubmed-meshheading:20191326-Time Factors,
pubmed-meshheading:20191326-Treatment Outcome,
pubmed-meshheading:20191326-Tumor Necrosis Factor-alpha,
pubmed-meshheading:20191326-Up-Regulation,
pubmed-meshheading:20191326-Vincristine
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
|
| pubmed:affiliation |
Equipe Pathologie des Cellules Lymphoïdes, UMR CNRS 5239, Université Claude Bernard, Lyon, France. ewamaranda@wp.pl
|
| pubmed:publicationType |
Journal Article
|